Researchers at the University of Michigan Comprehensive Cancer Center have discovered two cancer-spurring gene rearrangements that may trigger 5 to 7 percent of all breast cancers.

About half of prostate cancers have a genetic anomaly that appears to make tumor cells responsive to a new class of cancer-fighting drugs.

Researchers at the University of Michigan Comprehensive Cancer Center have identified a genetic anomaly that may drive the aggressive spread of a rare subset of prostate cancers.

Drugs should be developed to target gene fusions in prostate cancer, research shows.

Researchers link hormone to creation of gene fusion in prostate cancer ANN ARBOR, Mich., Oct.